Glenmark Pharmaceuticals, USA has received final approval by the United States Food & Drug Administration (US FDA) for Metronidazole Vaginal Gel, 0.75 per cent, the generic version of MetroGel-Vaginal Gel, 0.75 per cent, of Bausch Health US, LLC.

According to IQVIATM sales data for the 12 month period ending November 2021, the MetroGel- Vaginal Gel, 0.75 per cent market achieved annual sales of approximately $60.4 million.

Glenmark’s current portfolio consists of 173 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA.